Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

Chiara Funaioli, Carmine Pinto, Vita Mutri, Francesca Di Fabio, Claudio Ceccarelli, Andrea Angelo Martoni

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III disease should be defined by understanding which patients have a higher recurrence risk. Many studies have investigated several molecular markers, but none has been definitively associated with patient outcome. We present a review of studies that have evaluated the immunohistochemical correlation between expression of some biomarkers, such as thymidylate synthase, p53, Ki-67, Bcl-2, and microsatellite instability status expressed by Mut-L homologue I and Mut-S homologue 2 proteins, and the prognosis of patients with stage II/III colorectal cancer. We have evaluated studies in which ≥ 100 patients were involved in an effort to ensure a representative study group. The only biomarker likely to have a prognostic value is microsatellite instability status, which correlated with a better prognosis.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalClinical Colorectal Cancer
Volume6
Issue number1
DOIs
Publication statusPublished - 2006

Fingerprint

Colorectal Neoplasms
Microsatellite Instability
MutS Homolog 2 Protein
Biomarkers
Thymidylate Synthase
Adjuvant Chemotherapy
Recurrence
Therapeutics

Keywords

  • Biomarkers
  • Immunohistochemistry
  • Prognostic factors
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value? / Funaioli, Chiara; Pinto, Carmine; Mutri, Vita; Di Fabio, Francesca; Ceccarelli, Claudio; Martoni, Andrea Angelo.

In: Clinical Colorectal Cancer, Vol. 6, No. 1, 2006, p. 38-45.

Research output: Contribution to journalArticle

Funaioli, Chiara ; Pinto, Carmine ; Mutri, Vita ; Di Fabio, Francesca ; Ceccarelli, Claudio ; Martoni, Andrea Angelo. / Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?. In: Clinical Colorectal Cancer. 2006 ; Vol. 6, No. 1. pp. 38-45.
@article{fd004719ab004e08b46a1a5fd3188c1d,
title = "Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?",
abstract = "As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III disease should be defined by understanding which patients have a higher recurrence risk. Many studies have investigated several molecular markers, but none has been definitively associated with patient outcome. We present a review of studies that have evaluated the immunohistochemical correlation between expression of some biomarkers, such as thymidylate synthase, p53, Ki-67, Bcl-2, and microsatellite instability status expressed by Mut-L homologue I and Mut-S homologue 2 proteins, and the prognosis of patients with stage II/III colorectal cancer. We have evaluated studies in which ≥ 100 patients were involved in an effort to ensure a representative study group. The only biomarker likely to have a prognostic value is microsatellite instability status, which correlated with a better prognosis.",
keywords = "Biomarkers, Immunohistochemistry, Prognostic factors, Survival",
author = "Chiara Funaioli and Carmine Pinto and Vita Mutri and {Di Fabio}, Francesca and Claudio Ceccarelli and Martoni, {Andrea Angelo}",
year = "2006",
doi = "10.3816/CCC.2006.n.019",
language = "English",
volume = "6",
pages = "38--45",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

AU - Funaioli, Chiara

AU - Pinto, Carmine

AU - Mutri, Vita

AU - Di Fabio, Francesca

AU - Ceccarelli, Claudio

AU - Martoni, Andrea Angelo

PY - 2006

Y1 - 2006

N2 - As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III disease should be defined by understanding which patients have a higher recurrence risk. Many studies have investigated several molecular markers, but none has been definitively associated with patient outcome. We present a review of studies that have evaluated the immunohistochemical correlation between expression of some biomarkers, such as thymidylate synthase, p53, Ki-67, Bcl-2, and microsatellite instability status expressed by Mut-L homologue I and Mut-S homologue 2 proteins, and the prognosis of patients with stage II/III colorectal cancer. We have evaluated studies in which ≥ 100 patients were involved in an effort to ensure a representative study group. The only biomarker likely to have a prognostic value is microsatellite instability status, which correlated with a better prognosis.

AB - As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III disease should be defined by understanding which patients have a higher recurrence risk. Many studies have investigated several molecular markers, but none has been definitively associated with patient outcome. We present a review of studies that have evaluated the immunohistochemical correlation between expression of some biomarkers, such as thymidylate synthase, p53, Ki-67, Bcl-2, and microsatellite instability status expressed by Mut-L homologue I and Mut-S homologue 2 proteins, and the prognosis of patients with stage II/III colorectal cancer. We have evaluated studies in which ≥ 100 patients were involved in an effort to ensure a representative study group. The only biomarker likely to have a prognostic value is microsatellite instability status, which correlated with a better prognosis.

KW - Biomarkers

KW - Immunohistochemistry

KW - Prognostic factors

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745917973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745917973&partnerID=8YFLogxK

U2 - 10.3816/CCC.2006.n.019

DO - 10.3816/CCC.2006.n.019

M3 - Article

C2 - 16796790

AN - SCOPUS:33745917973

VL - 6

SP - 38

EP - 45

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 1

ER -